TCTMD

Talking Points

A selection of the best interviews conducted by physician leaders and recorded at cardiology conferences around the globe.06f763f0-76e5-11f0-bb7c-8557ae1d8a8b

No dejes de visitar la web del podcast y apoyar a su creador: soundcloud.com

Autor

TCTMD

Categoría

Science

Web del podcast

soundcloud.com

Último episodio

14 de oct. de 2026

¿Dónde escuchar?

Podcasts en la app Replaio Radio Muy pronto

Los podcasts llegarán muy pronto a la app. Instálala ahora y sé el primero en descubrir una forma totalmente nueva de vivir los podcasts

Descárgala en Google Play Instálala gratis Android casi 10 M de descargas · valoración de 4,8 iOS muy pronto

Episodios

The ECLS-SHOCK Trial 23.10.2024

Holger Thiele and C. Michael Gibson discuss the impact of VA-ECMO on patients with acute MI and advanced cardiogenic shock.

The STOPDAPT-3 Trial 09.10.2024

Masahiro Natsuaki and C. Michael Gibson discuss this latest randomized comparison of prasugrel monotherapy and DAPT with aspirin for patients undergoing PCI.

The ILUMIEN IV Trial 02.10.2024

Ziad Ali and C. Michael Gibson take a deeper dive into this comparison of OCT- and angiography-guided PCI.

OCT vs IVUS vs Angiography: A Meta-analysis 11.09.2024

Gregg Stone and C. Michael Gibson discuss an updated meta-analysis addressing intravascular imaging in DES implantation.

The ATTRibute-CM Trial 04.09.2024

Julian Gillmore and C. Michael Gibson discuss the efficacy of acoramidis for patients with transthyretin amyloid cardiomyopathy.

The ADVENT Trial 14.08.2024

Vivek Reddy and C. Michael Gibson compare pulsed field ablation versus thermal ablation for patients with paroxysmal atrial fibrillation.

The ARAMIS Trial 07.08.2024

Mathieu Kerneis and C. Michael Gibson compare outcomes of patients treated with anakinra, a new therapy for acute myocarditis, or placebo.

The NITRATE-CIN Trial 31.07.2024

Dan Jones and C. Michael Gibson discuss whether inorganic nitrate reduces contrast-induced nephropathy after angiography in ACS patients.

The DICTATE-AHF Trial 10.07.2024

Zachary Cox and C. Michael Gibson discuss whether early dapagliflozin initiation is safe and effective for patients with acute heart failure.

The RIGHT Trial 03.07.2024

Shaoping Nie, Gilles Montalescot, and C. Michael Gibson discuss prolonged anticoagulation after primary PCI for patients with MI.

Four-Year Results: The EVOLUT Low Risk Trial 12.06.2024

Michael J. Reardon and C. Michael Gibson discuss the trial's 4-year results in low-surgical-risk patients with severe aortic stenosis randomized to self-expanding TAVI or SAVR.

The AGENT IDE Trial 05.06.2024

Robert W. Yeh and C. Michael Gibson discuss the primary outcomes of this eagerly awaited trial comparing the AGENT paclitaxel-coated balloon with conventional balloon angioplasty for in-stent restenosis.

The TRISCEND II Trial 22.05.2024

Susheel K. Kodali and C. Michael Gibson discuss transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation.

The VIVA Trial 15.05.2024

Josep Rodés-Cabau and C. Michael Gibson discuss the benefits of TAVI versus SAVR in patients with severe aortic stenosis and small aortic annuli.

The SELECT Trial 01.05.2024

A. Michael Lincoff and C. Michael Gibson discuss the cardiovascular impact of semaglutide in patients with overweight or obesity but without diabetes.

The MINT Trial 17.04.2024

Jeffrey Carson and Serge Korjian discuss restrictive versus liberal blood transfusion in patients with MI and anemia.

The ORBITA-2 Trial 03.04.2024

Christopher Rajkumar, Rasha Al-Lamee, and C. Michael Gibson discuss this randomized trial of PCI versus a placebo procedure for stable angina.

The ARIE-HM3 Trial 14.03.2024

Mandeep Mehra and C. Michael Gibson discuss whether or not aspirin is needed for patients with left ventricular assist devices in advanced heart failure.

The AZALEA - TIMI Trial 11.03.2024

Christian T. Ruff and C. Michael Gibson discuss the primary results of a randomized trial testing the efficacy of abelacimab versus rivaroxaban for stroke prevention in atrial fibrillation.

The heart-1 Trial of VERVE-101 21.02.2024

Andrew Bellinger, Sek Kathiresan, and C. Michael Gibson talk about the phase 1b trial of what investigators hope may be a one-time genetic fix for hyperlipidemia.

Lepodisiran Phase I Trial 07.02.2024

Steven Nissen and C. Michael Gibson discuss the efficacy and safety of lepodisiran, an extended duration short-interfering RNA meant to reduce lipoprotein (a).

CLEAR Outcomes Subanalysis 24.01.2024

Paul Ridker and C. Michael Gibson discuss whether residual inflammatory risk or residual cholesterol risk is a more effective predictor of CV events among patients treated with statins.

The AXIOMATIC - SSP Trial 10.01.2024

Mike Sharma and C. Michael Gibson discuss managing acute thromboembolic events in secondary stroke using antithrombotic treatment with factor XIa inhibition.

The EBRAVE - AF Trial 03.01.2024

Axel Bauer and C. Michael Gibson talk about whether smartphone-based screening can effectively detect atrial fibrillation in elderly, at-risk patients.

The INVICTUS Trial 07.12.2023

Ganesan Karthikeyan and C. Michael Gibson compare the efficacy of rivaroxaban versus vitamin K agonists for patients with rheumatic heart disease associated atrial fibrillation

Escucha el podcast Talking Points en Replaio

Radio y podcasts en una sola app - gratis y sin registro. Instálala hoy y no te pierdas el estreno

Descárgala en Google Play

Replaio no es editor de podcasts; los nombres de los programas, las portadas y el audio pertenecen a sus autores y se distribuyen a través de canales RSS públicos